Jasper Therapeutics cae un 22%: Un enigma de la biotecnología se revela a medida que las grandes empresas del sector fracasan.

Summary
• Jasper Therapeutics (JSPR) trades at $1.6183, down 21.06% from its previous close of $2.05
• Intraday range spans $1.501 to $1.935, signaling extreme volatility
• Sector leader Amgen (AMGN) declines 3.28%, hinting at biotech sector fragility

Biotech stocks face a perfect storm as Jasper Therapeutics plunges to session lows amid a broader sector selloff. With Amgen dragging down the sector and JSPR trading near its 52-week low of $1.39, investors are scrambling to decipher the catalyst. The stock’s collapse—despite a lack of company-specific news—highlights the sector’s sensitivity to macroeconomic pressures and speculative positioning.

Biotech Sector Weakness Amplifies JSPR’s Downside
JSPR’s 21% intraday drop aligns with a broader biotech sector correction, as Amgen’s 3.28% decline underscores investor caution. While no direct company-specific news triggered the move, the stock’s collapse reflects a flight to liquidity amid rising interest rates and regulatory uncertainty. The sector’s exposure to high burn-rate models and long-term capital intensity makes it particularly vulnerable to macro shifts. JSPR’s low float and high short interest likely exacerbated the selloff, compounding pressure from broader market sentiment.

Biotech Sector Under Pressure as AMGN Drags Down Peers
The biotech sector is in retreat, with Amgen’s 3.28% decline amplifying risk-off sentiment. JSPR’s 21% drop mirrors the sector’s fragility, as investors reassess valuations for high-growth, low-revenue biotechs. While AMGN’s decline stems from macroeconomic concerns, smaller players like JSPR face added pressure from liquidity constraints and speculative positioning. The sector’s dynamic PE of -0.51 further highlights earnings challenges, with JSPR’s 52-week high of $7.19 now a distant memory.

Options and Technicals: Navigating JSPR’s Volatility
• MACD: 0.0184 (bullish divergence), Signal Line: -0.0101 (bearish), Histogram: 0.0285 (positive momentum)
• RSI: 74.29 (overbought), Bollinger Bands: $1.6447 (lower band), $1.8175 (middle band)
• 200D MA: $3.32 (far above price), 30D MA: $1.79 (near-term support)

JSPR’s technicals paint a mixed picture: RSI suggests overbought conditions, while MACD hints at divergent momentum. The stock is trading near its 200-day moving average ($3.32) and 30-day MA ($1.79), with the lower Bollinger Band ($1.64) acting as critical support. Given the sector’s fragility and JSPR’s low float, aggressive short-term strategies may outperform. Two options stand out:

• JSPR20260220C1.5 (Call, $1.5 strike, 2026-02-20 expiry):
- IV: 154.55% (high volatility)
- Leverage Ratio: 4.06% (moderate)
- Delta: 0.665 (moderate sensitivity)
- Theta: -0.00425 (moderate time decay)
- Gamma: 0.4177 (high sensitivity to price moves)
- Turnover: 105 (liquid)
- Payoff (5% downside): $0.08 per share (max(0, 1.538 - 1.5))
- Why: High gamma and IV make this call ideal for a rebound scenario, with liquidity ensuring trade execution.

• JSPR20260417P1.5 (Put, $1.5 strike, 2026-04-17 expiry):
- IV: 181.84% (high volatility)
- Leverage Ratio: 3.25% (moderate)
- Delta: -0.284 (moderate bearishness)
- Theta: -0.00222 (moderate decay)
- Gamma: 0.219 (moderate sensitivity)
- Turnover: 100 (liquid)
- Payoff (5% downside): $0.08 per share (max(0, 1.5 - 1.538))
- Why: High IV and liquidity make this put a hedge against further declines, with gamma offering protection against volatility spikes.

Action: Aggressive bulls may consider JSPR20260220C1.5 into a bounce above $1.79, while bears should monitor JSPR20260417P1.5 for a breakdown below $1.64.

Backtest Jasper Therapeutics Stock Performance
The backtest of JSPR's performance after a -21% intraday plunge from 2022 to now shows mixed results. The 3-Day win rate is 44.93%, the 10-Day win rate is 43.54%, and the 30-Day win rate is 39.17%. However, the returns over these periods are negative, with a -1.21% return over 3 days, a -1.56% return over 10 days, and a -1.81% return over 30 days. The maximum return during the backtest was -0.12%, which occurred on the 0 day, indicating that the stock did not recover its intraday losses even in the short term.

JSPR at Crossroads: Sector Turbulence or Catalyst-Driven Collapse?
JSPR’s 21% plunge reflects biotech sector fragility, with Amgen’s 3.28% decline amplifying risk-off sentiment. While technicals suggest a potential rebound near $1.79, the stock’s proximity to its 52-week low ($1.39) raises concerns about liquidity. Investors should watch for a breakdown below $1.64 or a sustained move above $1.81 to gauge direction. Given the sector’s exposure to macroeconomic shifts, JSPR’s path will likely mirror AMGN’s trajectory. Act now: Position for a rebound with JSPR20260220C1.5 or hedge with JSPR20260417P1.5, and monitor AMGN’s performance as a sector barometer.